Physician profile
Derek E Thomas
NPI 1508187683
$1,281.92
in general payments reported to CMS, 2019-2025
25 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.83 · 2020: $149 · 2021: $77.79 · 2022: $306 · 2023: $238 · 2024: $124 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $288.61 | 2020-2025 | Opdivo, Reblozyl |
| Pfizer INC. | $126.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $125.35 | 2019-2025 | |
| Amgen INC. | $99.95 | 2020 | |
| Coherus Oncology, INC. | $88.71 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $82.59 | 2022-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $62.58 | 2025 | |
| Array Biopharma INC | $48.80 | 2024 | Lorbrena, Braftovi, Mektovi |
| Janssen Pharmaceuticals, INC | $40.00 | 2019 | |
| Seagen INC. | $38.13 | 2022-2023 | Tukysa |
| Celgene Corporation | $36.24 | 2024-2025 | Reblozyl |
| Gilead Sciences, INC. | $23.50 | 2025 | Trodelvy |
| Eisai INC. | $23.14 | 2021 | |
| Beigene USA, INC. | $22.33 | 2022 | |
| Lilly USA, LLC | $20.14 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.89 | 2025 | Polivy |
| Taiho Oncology, INC. | $19.33 | 2023 | |
| Foundation Medicine, INC. | $17.69 | 2023 | Foundationone Cdx |
| Regeneron Healthcare Solutions, INC. | $17.20 | 2024 | Libtayo |
| Incyte Corporation | $15.77 | 2023 | Monjuvi, Jakafi |
| Novo Nordisk INC | $14.47 | 2019 | |
| Daiichi Sankyo INC. | $14.45 | 2023 | Enhertu |
| Jazz Pharmaceuticals INC. | $13.48 | 2022 | |
| Immunogen, INC. | $13.00 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $9.96 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.